EVALUATION OF DRUG-DRUG INTERACTION BETWEEN THE NOVEL cPLA2 INHIBITOR AK106-001616 AND METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS.
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2014
Price : $35 *
At a glance
- Drugs AK 106-001616 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Asahi Kasei; Asahi Kasei Pharma America Corp
- 09 Apr 2014 New trial record
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.